Clinical Trials Logo

Newly Diagnosed Glioblastoma clinical trials

View clinical trials related to Newly Diagnosed Glioblastoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03619239 Completed - Clinical trials for Newly Diagnosed Glioblastoma

Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma

GBM
Start date: June 20, 2018
Phase: Phase 1
Study type: Interventional

Patients will be enrolled in two stages: - Dose-escalation stage: Approximately 12-24 patients will be enrolled.

NCT ID: NCT03345095 Completed - Clinical trials for Newly Diagnosed Glioblastoma

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

MIRAGE
Start date: July 26, 2018
Phase: Phase 3
Study type: Interventional

The standard of care for newly diagnosed glioblastoma includes surgery, involved-field radiotherapy, and concomitant and six cycles of maintenance temozolomide chemotherapy, however the prognosis remains dismal. Marizomib has been tested in patients with newly diagnosed and recurrent glioblastoma in phase I and phase II studies. In patients with recurrent glioblastoma, marizomib was administered as a single agent or in combination with bevacizumab (NCT02330562). Based on encouraging observations, a phase I/II trial of marizomib in combination with Temozolomide+Radiotherapy(TMZ/RT) followed by Temozolomide (TMZ) in newly diagnosed glioblastoma has been launched (NCT02903069) which explores safety and tolerability of this triple combination and which shall help to determine the dose for further clinical trials in glioblastoma. In this context, given that marizomib has been established as a safe addition to the standard TMZ/RT -->TMZ, a phase III study is considered essential to establishing its impact on overall survival.

NCT ID: NCT01805453 Completed - Clinical trials for Newly-diagnosed Glioblastoma

Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma

ASTER
Start date: March 29, 2013
Phase: Phase 3
Study type: Interventional

To assess the efficacy of an Angiotensin-II inhibitor (Losartan) to reduce peritumoral edema in newly diagnosed glioblastoma patients.